StockWatch
·

Data Patterns (India) Ltd Q1 FY27 Results

DATAPATTNSQ1 FY27 Results
Filing
Result:Weak· Market: DownMargin squeezeBase effect

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue116.03 Cr66.3%16.8%
Total Income123.34 Cr64.8%12.3%
Expenditure93.86 Cr42.3%23.6%
PBT29.48 Cr84.3%13.2%
Net Profit22.06 Cr84.1%13.5%
OPM27.04%28.88pp5.26pp
NPM17.89%21.59pp5.32pp
EPS3.9484.1%13.4%
View full financials

PAT fell 13.5% YoY on cost-driven margin compression (OPM ~27% vs ~32%) even as revenue grew 16.8%, undershooting management's own 20-25% growth / 38-40% margin guidance, though the sequential collapse is a normal Q1 seasonality artifact for defence electronics.

DATAPATTNS · Q1 FY-2027 · THE VERDICT

Margin Squeeze and Order Delays Test Confidence in FY Guidance

Data Patterns missed Q1 revenue guidance (16.8% vs. 20-25%) and saw PAT decline 13.5% YoY despite top-line growth. The quarter reveals margin pressure and order timing risk that management must navigate to justify reaffirmed full-year targets.

07 Aug 2026 · 6 min read
Revenue YoY growth

16.8%

vs 20-25% FY guidance

PAT YoY decline

-13.5%

despite revenue growth

EBITDA margin

27%

vs 35-40% target

Gross margin

78.9%

flat YoY, signal intact

The core tension: PAT fell while revenue grew

Data Patterns delivered ₹116 Cr in Q1 revenue, growing 16.8% year-on-year. On the surface, that's a growth story. But profit after tax came in at ₹22.1 Cr, down 13.5% from the year-ago quarter—a signal that operating leverage has turned negative. With gross margins stable at 78.9%, the gap sits in the operating expense line, chiefly EBITDA margin compression from 35-40% guidance to just 27% in the quarter.

Where the margin pressure came from

Management attributed the 800-basis-point EBITDA shortfall to two factors: elevated employee costs for capability expansion and a shift in product mix. The CFO noted that gross margins remained healthy at 78.9%, indicating product quality held. The issue is structural near-term headwind—capex on headcount and facility investments—not a quality concern. But the magnitude of the squeeze (27% vs. 35-40% guidance) and the lack of a stated recovery timeline raise a critical question: how confident can we be that EBITDA margins recover to guidance levels by year-end?

Management claims vs. what holds up

Healthy 17% YoY revenue growth

Delivered 16.8% YoY; below 20-25% FY guidance

Overstated

Strong gross margins at 78.9%

Held firm; EBITDA margin 27% vs 35-40% due to high overheads

Supported (incomplete)

PAT margin 19% reflecting temporary uneven revenue impact

NPM 17.9%; PAT down 13.5% YoY despite revenue growth

Contradicted

Customer approval delays caused revenue slip

QoQ revenue down 66.4%; slip amount unquantified

Partial

Order book at ₹2,654 Cr provides healthy visibility

₹1,734 Cr negotiated, unconfirmed, delayed 6+ months; confirmed ₹920 Cr only

Mixed

What changed on this call

  • Margin reset downward: EBITDA now 27% vs. 35-40% guidance—employee costs and product mix now structural near-term headwinds

  • Order conversion timeline slipped: ₹1.7 Cr negotiated orders facing ~2-month delay; large program stretched 6+ months

  • Revenue growth deceleration risk: Q1 at 16.8% YoY; FY27 target reaffirmed at 20-25% but execution risk evident

  • Export pipeline accelerating: New wins in Europe/UK (antenna, signal processor, civil aviation) with material revenue in 6-12 months

  • Capex intensity rising: ₹150-200 Cr over 2 years for production, test equipment, facilities—signals conviction but lumpy cash flow risk

The bull-bear ledger

  • Order book ₹2.6 Cr provides 6-9 month visibility; ₹2k Cr FY27 target diversifies concentration risk

  • Gross margins stable at 78.9%—pricing power intact despite margin compression

  • Strong balance sheet: ₹530 Cr cash, net debt-free; capex fully self-funded

  • Defense indigenization tailwind + export traction create ₹40-50k Cr addressable TAM

  • Q1 revenue missed FY guidance (16.8% vs 20-25%); execution risk on ₹2k Cr target unresolved

  • PAT declined 13.5% YoY despite revenue growth—deteriorating operating leverage, cost structure misaligned

  • EBITDA margins 27% vs 35-40% guidance with no recovery timeline; margin recovery unproven

  • ₹1.7 Cr negotiated orders (65% of book) unconfirmed, delayed 6+ months; concentration risk from single program

  • ₹150-200 Cr capex committed on uncertain pipeline; ROI at risk if orders slip

Risks, ranked by how much they should concern a holder

1

High
Risk

Order conversion delays widen execution gap

Why it matters

₹1.7 Cr negotiated orders (65% of book) stalled 6+ months. If delays extend, ₹2k Cr FY27 target unreachable, forcing guidance miss and capex under-utilization.

2

High
Risk

Margin recovery contingent on order ramp unproven

Why it matters

EBITDA 27% vs 35-40% guidance. No timeline for recovery. If order volume doesn't accelerate, employee costs remain a drag—threatens reaffirmed FY guidance credibility.

3

High
Risk

Revenue quality deteriorating despite top-line growth

Why it matters

PAT down 13.5% YoY while revenue up 16.8% signals negative operating leverage. If cost structure not rightsized, margins remain compressed even with order book.

4

Medium
Risk

Customer concentration and approval delays

Why it matters

Large single program drives ₹1.7 Cr delays (6+ months already). If stretches further, order-to-cash cycle unpredictable and quarterly revenue volatile.

5

Medium
Risk

Capex heavy on unconfirmed pipeline

Why it matters

₹150-200 Cr capex assumes order inflow justifies production ramp. If ₹2k Cr target misses or delays to FY28, capex ROI deteriorates and cash flow lumpy.

6

Medium
Risk

Export and counter-drone revenue speculative

Why it matters

Europe/UK traction and counter-drone orders cited with 3-6 month timelines but not in ₹2k Cr prospect. If slip, 'significant additional market' upside evaporates.

How the street is positioned

Data Patterns' stock closed at ₹4,380.70 on the day of this review. The post-result price action tells a story: day 1 saw a -4.06% sell-off, but recovered to +2.08% by day 3, only to fade back into negative territory at -1.56% by day 5. The pop did not hold, signaling the market remains skeptical despite the order book headline.

The stock trades 11.59% below its all-time high, but 105.57% above its 52-week low—a reminder it has more than doubled from its lows even after this quarter's stumble. Institutionally, flows are cautiously supportive: FII ownership added 93 basis points and DII added 141 basis points in the latest quarter. This reflects long-term defense indigenization conviction, even as near-term execution comes into question.

The valuation story hinges on whether Q1 was a timing blip (supported by gross margin stability and ₹2.6 Cr order book) or signals structural cost issues. The market is pricing in skepticism: the fade from day 1 to day 5 reflects wariness about management's ability to hit reaffirmed full-year margins and orders.

The debate

What to watch next
  • 1 · ₹1.7 Cr order conversions expected within ~2 months (Q2 FY27)

    Management expects negotiated order conversion soon. If conversions slip again, ₹2k Cr FY27 prospect becomes unachievable. Watch for formal order acknowledgments, not just verbal guidance.

  • 2 · Q2 EBITDA margin recovery trajectory

    EBITDA 27% in Q1 is 800 bps below guidance. Q2 must show sequential improvement to justify 35-40% FY target. Even 30-32% would signal recovery on track; stagnation at 27% would challenge credibility.

  • 3 · BrahMos seeker orders and jammer pod qualification (H2 FY27)

    BrahMos seekers expected FY27. Su-30 jammer pod qualification expected before December 2026. Both are material upside catalysts—success would validate pipeline confidence and de-risk execution.

Data Patterns' Q1 miss on revenue guidance and PAT decline despite top-line growth expose near-term execution risk. The company's structural story—defense indigenization, order book depth, export traction—remains compelling. But the path to reaffirmed FY margins and orders is not yet proven. This quarter is a steady-execution story, not a step-change. Management has the balance sheet (₹530 Cr cash) and pipeline (₹2.6 Cr order book) to navigate margin pressure, but credibility hinges on Q2-Q3 delivery. The number to track from here is EBITDA margin—recovery toward 35-40% in H2 would reset confidence, while stagnation below 30% would force a guidance miss. Hold for now; the debate resolves by mid-FY27.

Informational and educational content only. Not investment advice.